MedPath

Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic

Not Applicable
Completed
Conditions
Biliary Colic
Interventions
Drug: Saline
Registration Number
NCT02268955
Lead Sponsor
Valleywise Health
Brief Summary

The aim of this study is to assess the analgesic efficacy of intravenous ibuprofen given in the Emergency Department for the treatment of biliary colic. We hypothesize that intravenous ibuprofen will provide a clinically significant drop in self-reported patient pain level as measured by the visual analog scale.

Detailed Description

It is estimated over 20 million people aged 20-74 have gallbladder disease, with biliary colic being a common and painful symptom in these patients. Likely due to the relatively recent approval of intravenous ibuprofen use for fever and pain in adults, no assessment of its analgesic efficacy for biliary colic currently exists in the literature.

Utilizing a visual analog scale (VAS) for patient self-assessment of pain, this study will address this lack of evidence and identify intravenous ibuprofen's value as a novel analgesic in the treatment of biliary colic. Patients will be given a VAS at the time of study therapy administration, at 15-minute intervals during the first hour post-administration, and 30-minute intervals in the second hour. Though NSAID's have been extensively studied in the management of this phenomenon, this study aims to help optimize pain treatment of patients presenting to the Emergency Department with biliary colic, and potentially pave the way for future analgesic treatment comparison studies.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
22
Inclusion Criteria
  • Patients ages 18-55
  • Present to ED with right upper quadrant (RUQ) abdominal pain
  • Suspected diagnosis of biliary colic
  • Negative pregnancy test for women of childbearing potential (complete POC testing form)
  • No history of cholecystectomy
Exclusion Criteria
  • Patient age < 18 or > 55
  • Incarcerated
  • Hemodynamic instability
  • Inability to reliably self-report or communicate pain intensity and pain relief
  • Taking Warfarin
  • Cannot consent of are not competent to consent
  • Hepatic, renal, cardiac failure
  • NSAID or morphine allergy
  • History congenital bleeding diathesis or platelet dysfunction
  • Peptic ulcer diseases
  • Are otherwise unsuitable for the study in the opinion of the investigator/sub-investigators

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
IV Ibuprofen: Adults age 18-55 yearsIV IbuprofenPatients receiving intravenous ibuprofen therapy
Control Group: Adults age 18-55 yearsSalineSaline-only control group
Primary Outcome Measures
NameTimeMethod
Pain Score 120 Minutes After Study Medication Administration120 minutes post medication administration

Pain is measured on a visual analog scale 0=no pain and 10=worst pain imaginable.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Maricopa Integrated Health System

🇺🇸

Phoenix, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath